Monitoring vaccine responses in immune compromised patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to monitor and document vaccination responses, efficacy, and safety in immune compromised patients at various stages of their disease. It will collect data on vaccine responses and the evolution of serology against vaccine-preventable diseases over time. The study will also focus on optimizing vaccination status and standardizing practices for managing immunocompromised patients. By creating a registry, the project seeks to share expertise and improve vaccination strategies for this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Immune compromised patient or patient who will soon be immunocompromised
2. Informed consent as documented by signature

Exclusion Criteria:

1. Individual/parental inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, known/suspected non-compliance, substance abuse, etc.
2. Plan to move out of the country or have prolong absence in the next 2 months

Where it's running

• University Hospitals of Geneva
  Geneva, Switzerland Recruiting

Study contacts

• Principal investigator: Laure F Pittet, MD-PhD — University Hospitals of Geneva
• Study coordinator: Laure F Pittet, MD-PhD
• Email: laure.pittet@hcuge.ch
• Phone: 0223725481

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

  Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Outside of the US · NCT07680816

• Using FibroScan to guide lowering immune-suppressing drugs after liver transplant

  This will test whether using FibroScan to measure liver stiffness lets doctors safely reduce immunosuppressive drugs in adults at least 2 years after a liver transplant who don't have autoimmune liver disease or recent rejection.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07206277

• Preemptive genetic testing to guide tacrolimus treatment for kidney transplant patients

  This study will test whether doing a genetic test before transplant to guide tacrolimus dosing helps people on the kidney transplant waiting list stay safer and use health resources more efficiently.

  Recruiting Phase 4 Instituto de Investigación Hospital Universitario La Paz · Madrid, Madrid · NCT06701825

• Once-daily tacrolimus regimens during the first year after liver transplant

  This will try once-daily tacrolimus with mycophenolate to see if simpler dosing helps people take their medicines and protects the transplanted liver during the first year after a liver transplant.

  Recruiting at 17 sites Phase 4 University Hospital, Limoges · Besançon and 17 other locations · NCT06354179

• Observational study on infections in transplant patients in Germany

  This study looks at how infections affect transplant patients in Germany to see what makes some people more likely to get infections and how it impacts their organ health over time.

  Recruiting Technical University of Munich · München · NCT06346665

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.